Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TNXP Tonix Pharmaceuticals

Watchlist
1.870
-0.120-6.03%
Close 06/24 16:00 ET
1.730
-0.14-7.49%
Pre Mkt Price 06/27 06:49 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.010
Open
1.980
Turnover
9.08M
Low
1.860
Pre Close
1.990
Volume
4.76M
Market Cap
35.04M
P/E(TTM)
Loss
52wk High
35.200
Shares
18.74M
P/E(Static)
Loss
52wk Low
1.630
Float Cap
35.02M
Bid/Ask %
50.00%
Historical High
1318399.341
Shs Float
18.73M
Volume Ratio
1.68
Historical Low
1.630
Dividend TTM
--
Div Yield TTM
--
P/B
0.17
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
25.41%
Amplitude
7.54%
Avg Price
1.908
Lot Size
1
Float Cap
35.02M
Bid/Ask %
50.00%
Historical High
1318399.341
Shs Float
18.73M
Volume Ratio
1.68
Historical Low
1.630
Dividend TTM
--
P/B
0.17
Dividend LFY
--
Turnover Ratio
25.41%
Amplitude
7.54%
Avg Price
1.908
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company’s infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
CEO: Lederman M.D., Seth
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top